Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPHA-SOLAR long-term open-label trial of STAR-0215 (Navenibart) in hereditary angioedema
2023-506540-16-01Phase 2Authorised
- Sponsor
- Astria Therapeutics
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of navenibart in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2), sponsored by Astria Therapeutics. Primary endpoint: Incidence of adverse events. Planned start Nov 2024; status: authorised.
02
Drugs
navenibart
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on 2023-506540-16-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506540-16-01.